Advertisement
(Logo: http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO
"David Southwell brings more than twenty years of experience andsignificant accomplishment to HGS in financial strategy, planning and businessdevelopment," said H. Thomas Watkins, President and Chief Executive Officer,HGS. "We look forward to benefiting from David's experience and insight as wecontinue our transformation into a fully commercial biopharmaceutical company.We are pleased to welcome him to our Board."
Advertisement
During his fourteen-year tenure at Sepracor, Mr. Southwell advancedthrough a series of senior management positions with increasing responsibilityin finance, corporate planning, development and licensing. He was responsiblefor raising approximately $3 billion through public equity offerings andprivate placements of convertible debt securities. Prior to joining Sepracor,Mr. Southwell was Vice President, Investment Banking Division, at LehmanBrothers in New York.
Mr. Southwell graduated from Rice University, and received his M.B.A. fromthe Tuck School of Business at Dartmouth College. Mr. Southwell serves asChairman of the Board of Directors for BioSphere Medical, Inc. and is a memberof the Board of Directors of PTC Therapeutics, Inc. He is also Chairman ofthe Tuck School of Business MBA Advisory Board and a member of the Tuck Schoolof Business "Investing for Excellence" Capital Campaign Steering Committee.
ABOUT HUMAN GENOME SCIENCES
The mission of HGS is to apply great science and great medicine to bringinnovative drugs to patients with unmet medical needs.
The HGS clinical development pipeline includes novel drugs to treathepatitis C, lupus, inhalation anthrax, cancer and other immune-mediateddiseases. The Company's primary focus is rapid progress toward thecommercialization of its two key lead drugs, Albuferon(R) (albinterferonalfa-2b) for hepatitis C and LymphoStat-B(R) (belimumab) for lupus. Phase 3clinical trials of both drugs are ongoing.
ABthrax(TM) (raxibacumab) is in late-stage development for the treatmentof inhalation anthrax, and the Company is on track to begin the delivery infall 2008 of 20,000 doses of ABthrax to the Strategic National Stockpile undera contract entered into with the U.S. Government in June 2006. HGS also hasthree drugs in clinical development for the treatment of cancer, including twoTRAIL receptor antibodies and a small-molecule antagonist of IAP (inhibitor ofapoptosis) proteins. In addition, HGS has substantial financial rights tothree products in the GSK clinical development pipeline.
For more information about HGS, please visit the Company's web site atwww.hgsi.com. Health professionals and patients interested in clinical trials
of HGS products may inquire via e-mail to [email protected] or bycalling HGS at (301) 610-5790, extension 3550.
HGS, Human Genome Sciences, ABthrax, Albuferon and LymphoStat-B aretrademarks of Human Genome Sciences, Inc.
SAFE HARBOR STATEMENT
This announcement contains forward-looking statements within the meaningof Section 27A of the Securities Act of 1933, as amended, and Section 21E ofthe Securities Exchange Act of 1934, as amended. The forward-lookingstatements are based on Human Genome Sciences' current intent, belief andexpectations. These statements are not guarantees of future performance andare subject to certain risks and uncertainties that are diffi
